{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-042817","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2023-12-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.410147+00:00","generated_at":"2026-06-07T06:21:06.542007+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avalo Therapeutics executes 1-for-240 reverse stock split to regain Nasdaq compliance","bullets":["Reverse split effective 5:00 PM ET Dec 28, 2023; shares trade split-adjusted Dec 29 under AVTX.","Shares outstanding reduced from ~192.4M to ~801,611; fractional shares rounded up to whole share.","Split raises per-share price to satisfy Nasdaq Capital Market minimum bid price rule.","No change to authorized shares or par value; options/warrants adjusted proportionally.","New CUSIP 05338F306; Equiniti Trust Company acting as exchange agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-042817","json":"https://secwatch.observer/filing/0001628280-23-042817.json","markdown":"https://secwatch.observer/filing/0001628280-23-042817.md","text":"https://secwatch.observer/filing/0001628280-23-042817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/0001628280-23-042817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/avtx-20231228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:21:06.542007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5104c026f97368803b8e291f8ecde346e725904d","claim":"Avalo Therapeutics, Inc.: Effected a reverse stock split at a ratio of 1-for-240 shares of common stock (effective 2023-12-28).","evidence_excerpt":"Avalo Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of Delaware for the purpose of effecting a reverse stock split (the “Reverse Stock Split”) of the outstanding shares of the Company’s common stock at a ratio of one (1) share for every two hundred forty (240) shares outstanding","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828023042817/0001628280-23-042817-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-28"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}